COMPASS THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $129.36M.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $17.57M.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $3.03M.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $53.58M.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $129.36M, a 636.30% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $17.57M, a 479.45% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $3.03M, a 96.00% decline from fiscal 2022.
- COMPASS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $75.74M, a 40.82% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $129.36M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $129.36M 10-Q · filed 2025-11-05 | |
| 2024-12-31 | $17.57M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $17.57M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $3.03M 10-K · filed 2025-02-27 | |
| 2023-06-30 | $3.03M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $75.74M 10-K · filed 2024-03-21 | |
| 2021-12-31 | $127.98M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $54.23M 10-K · filed 2022-03-18 | |
| 2020-06-30 | $53.58M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |